NCT07081984View on ClinicalTrials.gov

Study of TI-0093 Injection With Recurrent/Metastatic HPV-16 Positive Solid Tumors

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

September 1, 2025

Primary Completion Date

September 20, 2026

Study Completion Date

July 31, 2027

Conditions
HPV 16+ Recurrent or Metastatic CancerHNSCCCervical Cancer
Interventions
BIOLOGICAL

therapeutic tumor vaccine

TI-0093 injection will be administered intramuscularly on Day1, Day8, Day15, Day29 and Day43.

Trial Locations (1)

Unknown

Shanghai East Hospital, Shanghai

Sponsors

Lead Sponsor

Therorna
All Listed Sponsors
lead

Therorna

INDUSTRY

NCT07081984 - Study of TI-0093 Injection With Recurrent/Metastatic HPV-16 Positive Solid Tumors | Biotech Hunter | Biotech Hunter